SCHEMBL4494785

SCHEMBL4494785

NS(=O)(=O)c1cc(S(=O)(=O)N(c2ccccc2)c2ccccc2)c2cc(O)ccc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.49
PTGES O14684 1/20 0.41
LMNA P02545 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
GFER P55789 1/20 0.38
PKM P14618 1/20 0.38
MPL P40238 2/20 0.38
CA2 P00918 4/20 0.36
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA9 Q16790 2/20 0.36
ATM Q13315 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
ERAP1 Q9NZ08 1/20 0.34
NSD2 O96028 1/20 0.34
DUSP3 P51452 1/20 0.34
PTPN5 P54829 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4500848 0.87 PTGES (0.37) ESR1PTGESLMNANPC1RAB9A
SCHEMBL4497601 0.87 RORC (0.41) ESR1PTGESNPC1RAB9APOLB
SCHEMBL4497044 0.87 PTGES (0.45) ESR1PTGESLMNANPC1RAB9A
SCHEMBL4511797 0.87 PTGES (0.37) ESR1PTGESLMNANPC1RAB9A
SCHEMBL4511441 0.86 PTGES (0.40) ESR1PTGESLMNANPC1RAB9A
SCHEMBL4506268 0.85 CA1 (0.44) ESR1LMNAPOLBPKMCA2
SCHEMBL4512914 0.85 PTGES (0.39) ESR1PTGESLMNANPC1RAB9A
SCHEMBL4494085 0.85 PARP1 (0.40) ESR1PTGESNPC1RAB9AGAA
SCHEMBL4499043 0.84 CA2 (0.41) ESR1PTGESLMNANPC1RAB9A
SCHEMBL4503529 0.84 ESR1 (0.41) ESR1PTGESLMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090234014-A1 Naphthalene-Disulfonamides Useful for the Treatment of Inflammation BIOLIPOX AB (SE) 2009-09-17 US disclosed
EP-1934173-A1 NAPHTHALENE-DISULFONAMIDES USEFUL FOR THE TREATMENT OF INFLAMMATION Biolipox AB (SE) 2008-06-25 EP disclosed
WO-2007042817-A1 NAPHTHALENE-DISULFONAMIDES USEFUL FOR THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090234014-A1 Naphthalene-Disulfonamides Useful for the Treatment of Inflammation AREG, PRSS12, CXCL8 ESR1 1760/4885PTGES 41/4885LMNA 1939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.